Ernexa Therapeutics (ERNAW) Cash & Equivalents (2010 - 2026)

Ernexa Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 378.47% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (up 378.47% YoY), and the FY2025 full-year result was $1.9 million, up 8.96% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.2 million, up from $1.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $23.5 million in Q1 2022, with the low at $1.7 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $8.6 million across 5 years, with a median of $8.6 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 85.18% — and 2026, when it soared 378.47%.
• Ernexa Therapeutics' Cash & Equivalents stood at $15.5 million in 2022, then fell by 24.91% to $11.7 million in 2023, then slumped by 85.18% to $1.7 million in 2024, then grew by 8.96% to $1.9 million in 2025, then soared by 387.1% to $9.2 million in 2026.
• The last three Cash & Equivalents figures came in at $9.2 million (Q1 2026), $1.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.